Hepatocellular carcinoma remains one of the deadliest malignancies worldwide, ranking among the leading causes of cancer-related death. Its lethality stems largely from two clinical realities: a strong tendency to spread beyond the liver, and a stubborn resistance to conventional chemotherapeutic agents. Even as immunotherapy and targeted agents reshape the treatment landscape, many patients progress rapidly, and the molecular drivers of that progression have remained only partially mapped. The new findings add a critical piece to that map, positioning ApoA2 not as a passive biomarker but as an active participant in the tumor’s malignant behavior.

Apolipoproteins are best known for their role in lipid metabolism, shuttling cholesterol and triglycerides through the circulation. ApoA2 is a major constituent of HDL particles, and circulating levels of the protein have previously been associated with metabolic syndrome, cardiovascular disease, and, intriguingly, with altered risk profiles in several cancers. Epidemiological observations had hinted at connections between ApoA2 abundance and tumor behavior, but the mechanistic basis for such a link was unclear. The new study set out to determine whether ApoA2 is merely a correlate of disease severity or a genuine contributor to it.

Using hepatocellular carcinoma cell lines, animal models, and clinical tissue samples, the researchers found that ApoA2 expression is elevated in aggressive tumors and correlates with poor prognosis. When the team manipulated ApoA2 levels in laboratory models, the consequences were striking. Increasing ApoA2 enhanced the migratory and invasive capacity of cancer cells, while suppressing it markedly reduced metastatic potential. In mouse models of liver cancer, tumors with high ApoA2 activity spread more readily and responded poorly to chemotherapy, whereas lowering ApoA2 restored drug sensitivity and curtailed tumor dissemination.

The mechanistic heart of the paper lies in the HMGB1/IL-17A axis. HMGB1, or high-mobility group box 1, is a DNA-binding protein that normally resides in the nucleus, where it helps regulate gene expression and genome architecture. When cells are stressed, damaged, or activated by inflammatory signals, HMGB1 can be released into the extracellular space, where it acts as a danger signal, or alarmin, binding to receptors such as RAGE and Toll-like receptors to ignite inflammatory responses. The study demonstrates that ApoA2 promotes the secretion of HMGB1 from hepatocellular carcinoma cells, converting an intracellular housekeeping protein into an extracellular inflammatory messenger.

Once outside the cell, HMGB1 sets off a chain reaction. The researchers show that extracellular HMGB1 stimulates the production of interleukin-17A, a pro-inflammatory cytokine classically associated with Th17 immune cells but increasingly recognized as a product of the tumor microenvironment itself. IL-17A is known to fuel chronic inflammation, promote angiogenesis, and foster an immunosuppressive milieu that favors tumor growth. In this context, the ApoA2-HMGB1-IL-17A circuit appears to create a self-reinforcing inflammatory loop within and around the tumor, one that simultaneously drives cells toward invasive behavior and shields them from the cytotoxic effects of chemotherapeutic drugs.

The drug resistance component of the findings is particularly consequential. Chemotherapy for hepatocellular carcinoma has long been hampered by modest response rates, and understanding why some tumors shrug off treatment is a central question in the field. The study provides evidence that the HMGB1/IL-17A pathway activated by ApoA2 helps cancer cells survive drug-induced stress, likely through inflammatory survival signaling and alterations in the tumor microenvironment that blunt drug efficacy. When the researchers interfered with the axis, blocking HMGB1 or neutralizing IL-17A, the resistance phenotype weakened, suggesting that each node in the pathway represents a potential therapeutic target.

From a translational standpoint, the work carries several implications. First, ApoA2 could serve as a biomarker to identify patients whose tumors are predisposed to metastasis and treatment failure, allowing clinicians to stratify therapy more aggressively from the outset. Second, existing drugs or biologics that target IL-17A, some of which are already approved for inflammatory diseases such as psoriasis, could potentially be repurposed or adapted for hepatocellular carcinoma, either alone or in combination with chemotherapy or immunotherapy. Third, the identification of HMGB1 as a pivotal intermediary offers another intervention point, and HMGB1 inhibitors are an area of active pharmaceutical development.

The findings also resonate with a broader conceptual shift in cancer biology: the recognition that metabolic proteins and inflammatory circuits are deeply intertwined with malignant progression. Tumors do not evolve in isolation; they co-opt the body’s lipid transport machinery, danger-sensing systems, and immune signaling networks to advance their own agenda. The ApoA2/HMGB1/IL-17A axis is a vivid example of this co-option, linking a routine component of blood lipid particles to the inflammatory engine that powers metastasis and treatment resistance. It underscores why chronic inflammation of the liver, whether from viral hepatitis, alcohol, or fatty liver disease, creates such fertile ground for cancer, and why interrupting inflammatory signaling may be as important as attacking the cancer cells directly.

As with any preclinical study, important questions remain before the findings can change clinical practice. The precise molecular steps by which ApoA2 triggers HMGB1 release, the relative contributions of tumor cells versus immune cells to IL-17A production, and the safety of targeting this axis in patients with underlying liver disease all require further investigation. Human validation in large, prospective cohorts will be essential to confirm ApoA2’s prognostic value. Nevertheless, the study delivers a compelling and mechanistically grounded case that a familiar blood protein is an unexpected architect of liver cancer aggression, and it opens a concrete path toward therapies that could strip hepatocellular carcinoma of two of its most dangerous weapons: the ability to spread and the ability to survive treatment.

Subject of Research: The role of apolipoprotein A2 in promoting metastasis and drug resistance in hepatocellular carcinoma through the HMGB1/IL-17A inflammatory signaling axis.

Article Title: ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis

Article References: Fu, Z., Zhu, F., Fu, Z., Wang, C., Guan, T., Yuan, Y., Zhang, S., & Zhang, T. (2026). ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03317-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03317-2

Keywords: ApoA2, hepatocellular carcinoma, HMGB1, interleukin-17A, metastasis, drug resistance, liver cancer, inflammation, tumor microenvironment, biomarker, cytokine signaling, chemotherapy

Unlike protein-coding genes, long non-coding RNAs do not serve primarily as templates for producing proteins. Instead, they can regulate gene activity through several mechanisms, including interactions with DNA, chromatin-modifying proteins, transcription factors and messenger RNAs. Some long non-coding RNAs act as molecular scaffolds, bringing regulatory proteins into proximity; others influence the stability or translation of messenger RNAs. LINC02709 appears, according to the study’s title and reported conclusions, to function as a regulator of malignant behavior rather than as a conventional structural component of the cell. Its significance lies in how a non-coding transcript can reshape the phenotype of hepatocellular carcinoma cells and alter their relationship with immune cells in the surrounding liver.

The first process highlighted by the researchers is the expansion of stem cell-like characteristics within tumor cells. In cancer biology, “stemness” does not necessarily mean that a cell is a normal stem cell. It refers to a set of properties that may include the ability to self-renew, survive under stress, generate diverse tumor-cell populations and initiate new tumors more efficiently. These traits can make cancer cells resistant to treatment and better equipped to seed metastases. Tumor plasticity is particularly important in hepatocellular carcinoma because malignant cells can shift between different functional states in response to oxygen deprivation, nutrient limitation, inflammation or therapy. By increasing stem cell-like properties, LINC02709 may help a subset of liver cancer cells remain adaptable while moving through the metastatic cascade.

Metastasis is not a single event but a chain of biological challenges. Cancer cells must detach from the primary tumor, invade nearby tissue, enter blood or lymphatic vessels, survive circulation, exit at a distant organ and adapt to a new microenvironment. Most disseminated cells fail at one or more of these stages. Cells with enhanced stemness may have a greater chance of surviving these obstacles because they can withstand environmental stress and regenerate tumor populations after reaching a new site. The study’s central implication is that LINC02709 may support this process by shifting hepatocellular carcinoma toward a more flexible, resilient and metastasis-capable state. That possibility makes the RNA a candidate marker for aggressive disease and a potential target for future investigation.

The second mechanism involves Kupffer cells, which account for a substantial part of the liver’s innate immune environment. Positioned along the sinusoidal blood vessels, these macrophages continuously sample blood arriving from the gastrointestinal tract and help remove microbes, damaged cells and foreign particles. Their ability to engulf material, a process known as phagocytosis, is one of the liver’s essential defensive functions. In cancer, however, macrophages can be reprogrammed by signals released from tumor cells. They may become less effective at eliminating malignant cells or may adopt states that support tumor growth, tissue remodeling and immune suppression. The reported link between LINC02709 and reduced Kupffer cell phagocytosis suggests that the RNA may help hepatocellular carcinoma evade an important layer of local immune surveillance.

Phagocytosis begins when a macrophage recognizes molecular signals on the surface of a target cell. These signals can include antibodies, complement fragments or “eat-me” markers that distinguish damaged or abnormal cells from healthy tissue. Receptors on the macrophage then trigger cytoskeletal rearrangements, allowing the immune cell to surround and internalize its target. Tumors can interfere with this process by increasing “don’t-eat-me” signals, releasing immunosuppressive factors or altering the metabolism and signaling networks of macrophages. If LINC02709 contributes to this suppression, it could connect a cancer-cell-intrinsic program with a change in the behavior of nearby immune cells. Such a connection would help explain how metastatic tumor cells can avoid removal while simultaneously acquiring properties that favor dissemination.

The study therefore presents LINC02709 as more than a passive molecular signature. It may represent a regulatory node linking tumor plasticity with immune escape. This is important because cancer therapies often focus on one compartment at a time: treatments may directly attack tumor-cell division, while immunotherapies attempt to restore immune recognition. A molecule capable of influencing both the aggressiveness of malignant cells and the activity of Kupffer cells could offer a broader therapeutic entry point. Researchers may now investigate whether blocking LINC02709 reduces stemness, restores macrophage engulfment or limits metastatic growth in experimental models. Such work would also need to determine where the RNA acts inside the cell, which molecules it binds, and whether its effects depend on specific signaling pathways or tumor subtypes.

The findings could eventually have implications for diagnosis and treatment selection, although clinical use would require extensive validation. Measuring LINC02709 in tumor tissue, blood or other biological samples might help identify patients whose cancers have a higher metastatic potential, provided that reliable and specific assays can be developed. Therapeutically, strategies might include antisense oligonucleotides, small interfering RNAs or other approaches designed to reduce the RNA’s activity. However, targeting a long non-coding RNA presents challenges: its expression may vary between tissues, its structure can be difficult to define, and suppressing it must not disrupt essential functions in healthy cells. Restoring Kupffer cell activity would also need to be carefully controlled, since excessive macrophage activation could damage liver tissue or intensify inflammation.

For now, the report places LINC02709 among a growing group of non-coding regulators that are changing how scientists understand liver cancer progression. Hepatocellular carcinoma is shaped not only by mutations that drive uncontrolled growth, but also by reversible changes in cell identity and continuous communication with the immune microenvironment. By describing a relationship between LINC02709, cancer stem cell-like traits and impaired Kupffer cell phagocytosis, the study offers a framework for examining metastasis as both a tumor-cell and ecosystem-level process. The next stage will be to establish the molecular details, test whether the relationship holds across patient populations and determine whether disrupting LINC02709 can prevent spread without harming normal liver defenses. If those questions are answered, a once-overlooked non-coding RNA could become a useful guide to the biology—and potentially the treatment—of metastatic liver cancer.

Subject of Research: LINC02709, hepatocellular carcinoma metastasis, cancer stem cell-like properties and Kupffer cell phagocytosis

Article Title: LINC02709 facilitates hepatocellular carcinoma metastasis by increasing stem cell-like properties and suppressing Kupffer cell phagocytosis.

Article References: Wei, H., Li, W., Wu, X. et al. “LINC02709 facilitates hepatocellular carcinoma metastasis by increasing stem cell-like properties and suppressing Kupffer cell phagocytosis.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03276-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03276-8

Keywords: LINC02709, hepatocellular carcinoma, liver cancer, metastasis, long non-coding RNA, cancer stemness, Kupffer cells, phagocytosis, immune evasion